# A Study of WVT078 in Patients With Multiple Myeloma (MM)

> **NCT04123418** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **BIOLOGICAL:** WVT078
- **DRUG:** WHG626

## Key facts

- **NCT ID:** NCT04123418
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-05
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The decision was made for business reasons and was not based on any safety or tolerability concerns
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123418, "A Study of WVT078 in Patients With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04123418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*